US.MRNA · Moderna

{
  "risk": {
    "level": "High",
    "reason": "risk management score < 5/10",
    "position": {
      "score": 0.9,
      "details": {
        "atrPct": 5.913488525672775,
        "turnoverUsdM": 396.71708553,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.3
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.MRNA",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 53.4064,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 2.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 11.8,
      "take_profit_price": 68.6231,
      "target_multiplier": 1.9,
      "technical_strength": 1.78,
      "take_profit_percent": 13.3
    },
    "positionPoints": 0.9,
    "stopLossPoints": 0.6,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 11.82697705134555,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 70.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 53.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 17
  },
  "market": {
    "ma20": 58.101,
    "ma50": 59.8079,
    "close": 60.57,
    "prevClose": 59.81,
    "avgVolume20": 5127006,
    "volumeRatio": 1.28,
    "changePercent": 1.27
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 17,
    "details": {
      "ret_5d": 0.0628180382523249,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 17,
      "vcp_bonus": 0,
      "vol_ratio": 1.2867495655812664,
      "ret_points": 12,
      "vol_points": 4,
      "range_ratio": 0.8286350029197784,
      "volat_points": 0,
      "day_range_pct": 0.04622750536569254,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 70.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 50,
        "contribution": 2.5
      },
      {
        "raw": 11.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 58,
        "contribution": 11.6
      },
      {
        "raw": 6.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 45.33,
        "contribution": 6.8
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 4.9,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 49,
        "contribution": 4.9
      },
      {
        "raw": 21,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 70,
        "contribution": 21
      },
      {
        "raw": 1,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 10,
        "contribution": 1
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 53.8,
    "details": [
      "基本面分析總分: 2.5/5分",
      "資金流分析總分: 11.6/20分",
      "市場環境分析總分: 6.8/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 4.9/10分",
      "技術信號分析總分: 21/30分",
      "情緒分析: 1/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 2.5,
      "資金流": 11.6,
      "市場環境": 6.8,
      "情緒分析": 1,
      "技術信號": 21,
      "風險管理": 4.9
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0.75,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 396.71708553,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 2.4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.MRNA",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 700.7284982000001,
                "ma50": 713.8734013200001,
                "name": "QQQ",
                "close": 718.34003,
                "points": 1.4
              },
              "spy": {
                "ma20": 752.3020020999999,
                "ma50": 747.8392041399999,
                "name": "SPY",
                "close": 770.56,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 5.913488525672775,
          "atrPoints": 1,
          "cciPoints": 2.4,
          "vixPoints": 0,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 1,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 1,
              "positiveHits": 0,
              "sentimentScoreRaw": -0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141181051,
                "url": "https://finnhub.io/api/news?id=d9c163b5230fcbce2af75f65da199e675d0bba8f75a5b09c6bbcb0dcf09a881f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with a massive, non-dilutive liquidity boost while removing a significant overhang for […]",
                "category": "company",
                "datetime": 1786407501,
                "headline": "Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?"
              },
              {
                "id": 141175561,
                "url": "https://finnhub.io/api/news?id=4a562332d058d0f13b61c5826abf2babe330012f32e6d3088d4724981c07710d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.",
                "category": "company",
                "datetime": 1786377702,
                "headline": "FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market"
              },
              {
                "id": 141155648,
                "url": "https://finnhub.io/api/news?id=d9e90214fe03d4767733465ade546ee88cd239ba15f2c7dd159de8382fbf8fcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Net loss improved 5% on international partnerships and manufacturing gains.",
                "category": "company",
                "datetime": 1786156376,
                "headline": "Moderna (MRNA) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141147242,
                "url": "https://finnhub.io/api/news?id=6e64abe7f35a4500597d447a501575e2d06b96289d593836ace76e012eb9c542",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NasdaqGS:MRNA) has initiated a Phase 1 clinical trial in Canada for its investigational mRNA vaccine targeting Bundibugyo ebolavirus. The program addresses a strain of Ebola that currently has no approved vaccine and is positioned as part of Moderna's broader infectious disease portfolio. The trial involves collaboration with CEPI and Canadian public health authorities, with a stated focus on access for low and middle income countries. This kind of targeted vaccine work highlights...",
                "category": "company",
                "datetime": 1786108318,
                "headline": "Moderna (MRNA) Starts Phase 1 Canada Trial For Bundibugyo Ebola mRNA Vaccine"
              },
              {
                "id": 141149503,
                "url": "https://finnhub.io/api/news?id=6870e18d4d437dc9735084b362356556adcff40b5e1f22342eb3f986f385884a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The company says it expects to have mFlusiva ready for the upcoming 2026-2027 flu season, which runs from roughly October to May.",
                "category": "company",
                "datetime": 1786075260,
                "headline": "For Moderna’s Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off"
              },
              {
                "id": 141140831,
                "url": "https://finnhub.io/api/news?id=949f85a6afc00c6caf0a54c21311022fb79bb3057102c12440934d1547c1fde0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) is back in focus after the US Food and Drug Administration approved mFLUSIVA, the company’s mRNA based flu vaccine for adults aged 50 and over, sparking renewed interest in the stock. See our latest analysis for Moderna. The FDA approval of mFLUSIVA comes after a period of sharp swings in Moderna’s share price, with a 1-month share price return down 31.23% but a year to date share price return up 82.29%. At the same time, the 1-year total shareholder return of 110.61% contrasts...",
                "category": "company",
                "datetime": 1786050946,
                "headline": "Moderna (MRNA) Wins Flu Vaccine Approval, Is It Fully Priced?"
              },
              {
                "id": 141142439,
                "url": "https://finnhub.io/api/news?id=3fc6f65f8064897a597e60b3b7e44becfb2dae2f04dd5388984b98c1ca27162c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!",
                "category": "company",
                "datetime": 1786039280,
                "headline": "MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine"
              },
              {
                "id": 141137506,
                "url": "https://finnhub.io/api/news?id=64c4411f3130056dc8d8567d24917e366f3e522ac238fc8789f56ebd3c04e68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The approval makes mFLUSIVA Moderna’s fourth FDA-cleared product and the first messenger RNA-based flu vaccine.",
                "category": "company",
                "datetime": 1786036804,
                "headline": "MRNA Stock Pares Gains Despite FDA Green Light For First mRNA Flu Vaccine — But Retail Cheers Pivot Beyond COVID"
              }
            ],
            "raw_source": [
              {
                "id": 141181051,
                "url": "https://finnhub.io/api/news?id=d9c163b5230fcbce2af75f65da199e675d0bba8f75a5b09c6bbcb0dcf09a881f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with a massive, non-dilutive liquidity boost while removing a significant overhang for […]",
                "category": "company",
                "datetime": 1786407501,
                "headline": "Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?"
              },
              {
                "id": 141175561,
                "url": "https://finnhub.io/api/news?id=4a562332d058d0f13b61c5826abf2babe330012f32e6d3088d4724981c07710d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.",
                "category": "company",
                "datetime": 1786377702,
                "headline": "FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market"
              },
              {
                "id": 141175274,
                "url": "https://finnhub.io/api/news?id=d748c649d767517901cdba8efff57aa3b14812c64bab4e2a312033b7876c68b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "On this episode of Stock Movers: - RocketLab (RKLB) shares are higher this morning after rising Friday, following earnings from SpaceX last week. - Moderna (MRNA) shares are moving after last week's news that its mRNA flu shot won US approval in an FDA turnaround. - Intel (INTC) shares are moving after the company said it will be offering $15 billion in common stock, taking advantage of renewed interest in its business prospects during the artificial intelligence data center boom.",
                "category": "company",
                "datetime": 1786374977,
                "headline": "RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers"
              },
              {
                "id": 141177769,
                "url": "https://finnhub.io/api/news?id=9fc13a6f1f120c3d5712dbe2d97e5f0cc6fae4550b2463703edb7b77d3ef9238",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "https://youtu.be/H_RititNE8U",
                "category": "company",
                "datetime": 1786374019,
                "headline": "Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children"
              },
              {
                "id": 141173955,
                "url": "https://finnhub.io/api/news?id=8f8a6c94e14cda994096b4ea274ea3ef41e64e688ce7867132f30f540487144b",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
                "category": "company",
                "datetime": 1786365301,
                "headline": "Get insights into the top movers in the S&P500 index of Monday's pre-market session."
              },
              {
                "id": 141173544,
                "url": "https://finnhub.io/api/news?id=b941f9d258011d9774e73dcaf43578d9a7d9b0d74402a64bd442dab3aca6617f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241965815/image_2241965815.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna (MRNA) valuation in focus: weak Q2, cash outlook, FDA win for mFLUSIVA, pipeline risks and sales hurdles.",
                "category": "company",
                "datetime": 1786347053,
                "headline": "Moderna: I'm Still On Sell, But Here's What Would Change My Mind"
              },
              {
                "id": 141155648,
                "url": "https://finnhub.io/api/news?id=d9e90214fe03d4767733465ade546ee88cd239ba15f2c7dd159de8382fbf8fcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Net loss improved 5% on international partnerships and manufacturing gains.",
                "category": "company",
                "datetime": 1786156376,
                "headline": "Moderna (MRNA) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141150616,
                "url": "https://finnhub.io/api/news?id=97cc30b60f13c7af214f0c0afb17997cc515ad12a36ad63fdf4d3ec954ca3f5c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1786129501,
                "headline": "Stay informed with the top movers within the S&P500 index on Friday."
              },
              {
                "id": 141148910,
                "url": "https://finnhub.io/api/news?id=9bdba43fcab22b2cbe6b2e92788d4e69dd55e6b163385f9dbbc531c0004beafd",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.",
                "category": "company",
                "datetime": 1786120501,
                "headline": "Top S&P500 movers in Friday's session"
              },
              {
                "id": 141148372,
                "url": "https://finnhub.io/api/news?id=3746977f62a3f52bb06e4337c1c4785d5648c76514f4be482ffcb7b77884dadf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.",
                "category": "company",
                "datetime": 1786113900,
                "headline": "Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones"
              },
              {
                "id": 141147242,
                "url": "https://finnhub.io/api/news?id=6e64abe7f35a4500597d447a501575e2d06b96289d593836ace76e012eb9c542",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NasdaqGS:MRNA) has initiated a Phase 1 clinical trial in Canada for its investigational mRNA vaccine targeting Bundibugyo ebolavirus. The program addresses a strain of Ebola that currently has no approved vaccine and is positioned as part of Moderna's broader infectious disease portfolio. The trial involves collaboration with CEPI and Canadian public health authorities, with a stated focus on access for low and middle income countries. This kind of targeted vaccine work highlights...",
                "category": "company",
                "datetime": 1786108318,
                "headline": "Moderna (MRNA) Starts Phase 1 Canada Trial For Bundibugyo Ebola mRNA Vaccine"
              },
              {
                "id": 141158420,
                "url": "https://finnhub.io/api/news?id=815d119cb70a6c941f8f11ff450732683edd713eff6a2a1cb3a31627cf26ab5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moby summary of Roivant Sciences Ltd.'s Q1 2026 earnings call",
                "category": "company",
                "datetime": 1786105800,
                "headline": "Roivant Sciences Ltd. Q1 2026 Earnings Call Summary"
              },
              {
                "id": 141146398,
                "url": "https://finnhub.io/api/news?id=18887605dd87cf9a26e6068ca922418b72cc2859e699a008ce3f08ba711e5700",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie",
                "category": "company",
                "datetime": 1786100637,
                "headline": "Roivant Sciences Q1 Earnings Call Highlights"
              },
              {
                "id": 141145823,
                "url": "https://finnhub.io/api/news?id=7eeb3f1c50ce29db097d3f6725f03f44eba5c394319c532ac14e3a101602bae7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Dublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The \"Global Influenza Vaccine Market: 2026 Edition\" has been added to ResearchAndMarkets.com's offering. The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, expanding at a compound annual growth rate of approximately 7% between 2025 and 2030. Market growth is being supported by rising public health awareness, an expanding geriatric population, government immunization programs, recu",
                "category": "company",
                "datetime": 1786096440,
                "headline": "Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players"
              },
              {
                "id": 141149503,
                "url": "https://finnhub.io/api/news?id=6870e18d4d437dc9735084b362356556adcff40b5e1f22342eb3f986f385884a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The company says it expects to have mFlusiva ready for the upcoming 2026-2027 flu season, which runs from roughly October to May.",
                "category": "company",
                "datetime": 1786075260,
                "headline": "For Moderna’s Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off"
              },
              {
                "id": 141140831,
                "url": "https://finnhub.io/api/news?id=949f85a6afc00c6caf0a54c21311022fb79bb3057102c12440934d1547c1fde0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) is back in focus after the US Food and Drug Administration approved mFLUSIVA, the company’s mRNA based flu vaccine for adults aged 50 and over, sparking renewed interest in the stock. See our latest analysis for Moderna. The FDA approval of mFLUSIVA comes after a period of sharp swings in Moderna’s share price, with a 1-month share price return down 31.23% but a year to date share price return up 82.29%. At the same time, the 1-year total shareholder return of 110.61% contrasts...",
                "category": "company",
                "datetime": 1786050946,
                "headline": "Moderna (MRNA) Wins Flu Vaccine Approval, Is It Fully Priced?"
              },
              {
                "id": 141140832,
                "url": "https://finnhub.io/api/news?id=e5f8332b54bd5057e2f02f6f1a1b257c2fc58dcb8da287186370ec5fdd7711c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock fell Thursday after the Food and Drug Administration approved its mRNA-based flu shot, now called mFlusiva.",
                "category": "company",
                "datetime": 1786046999,
                "headline": "Moderna Dives Despite Hard-Fought FDA Win; Will Its Sprint Restart?"
              },
              {
                "id": 141140833,
                "url": "https://finnhub.io/api/news?id=377f7db9ee1ccb19cd52649e1d7a25544adaddf1cfc94bd7713c496aee749f28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt",
                "category": "company",
                "datetime": 1786043059,
                "headline": "Immunovant Q1 Earnings Call Highlights"
              },
              {
                "id": 141140972,
                "url": "https://finnhub.io/api/news?id=4a97cb2c93a9c2dbae51257069fddd4c5e262195e7fd25604102e666ed4523af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Roivant Sciences Ltd (ROIV) reports robust financials and key clinical milestones, including the brepocitinib launch and Moderna settlement, while navigating pipeline uncertainties.",
                "category": "company",
                "datetime": 1786042967,
                "headline": "Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong ..."
              },
              {
                "id": 141142439,
                "url": "https://finnhub.io/api/news?id=3fc6f65f8064897a597e60b3b7e44becfb2dae2f04dd5388984b98c1ca27162c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!",
                "category": "company",
                "datetime": 1786039280,
                "headline": "MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine"
              },
              {
                "id": 141137506,
                "url": "https://finnhub.io/api/news?id=64c4411f3130056dc8d8567d24917e366f3e522ac238fc8789f56ebd3c04e68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The approval makes mFLUSIVA Moderna’s fourth FDA-cleared product and the first messenger RNA-based flu vaccine.",
                "category": "company",
                "datetime": 1786036804,
                "headline": "MRNA Stock Pares Gains Despite FDA Green Light For First mRNA Flu Vaccine — But Retail Cheers Pivot Beyond COVID"
              },
              {
                "id": 141137139,
                "url": "https://finnhub.io/api/news?id=ea8cdd716db11d8a39e4d0739426a07c1de0c0ad54f47da59b9be87c2a541437",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Up to 911.5 million shares of SpaceX that are held by insiders and early investors are available to trade beginning Thursday.",
                "category": "company",
                "datetime": 1786030620,
                "headline": "SpaceX, Honeywell Aerospace, Sandisk, D-Wave, Datadog, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141135733,
                "url": "https://finnhub.io/api/news?id=26f7eff393b66776d3e8191329ee5ab9cc2932d8155f77c196e7b20729ff5f3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.",
                "category": "company",
                "datetime": 1786027860,
                "headline": "Moderna Just Got FDA Clearance for Flu Vaccine. The Stock Slips."
              },
              {
                "id": 141135734,
                "url": "https://finnhub.io/api/news?id=f58ddb6312b7b86c7ed90e4e46756b27cb0e6cf00e4f09253a3da1417aec8d3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock wavered Thursday after the Food and Drug Administration approved its mRNA-based flu shot, now called mFlusiva.",
                "category": "company",
                "datetime": 1786025636,
                "headline": "Moderna Wavers Despite Hard-Fought FDA Win; Will Its Sprint Restart?"
              },
              {
                "id": 141136784,
                "url": "https://finnhub.io/api/news?id=36d69d69a81b7a045aaeee6e062977c043dbbaf4dc639a27c093334a34b257a6",
                "image": "https://image.cnbcfm.com/api/v1/image/107249878-1685705682614-gettyimages-1369197035-366a7104_20d35d56-4f16-4497-b339-40f06443ab58.jpeg?v=1692790091&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "Here are some of the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1786023113,
                "headline": "Stocks making the biggest moves midday: UMW Holdings, Honeywell Aerospace, Macom, Peloton & more"
              },
              {
                "id": 141134031,
                "url": "https://finnhub.io/api/news?id=842cfcc89663b00eb959048a1e078321d2fab8f79c6fca68cf2d767b324e8670",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Memory stocks falter after guidance from Sandisk and Western Digital fails to meet Wall Street’s lofty expectations.",
                "category": "company",
                "datetime": 1786020780,
                "headline": "Sandisk, Western Digital, D-Wave, IonQ, AppLovin, Datadog, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141133671,
                "url": "https://finnhub.io/api/news?id=91c0194f617b9ce222be9f2c00c78db94f28ee70b970fb642bc4031e439b6786",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
                "category": "company",
                "datetime": 1786019701,
                "headline": "What's going on in today's pre-market session: S&P500 movers"
              },
              {
                "id": 141134298,
                "url": "https://finnhub.io/api/news?id=b4a6f17d531bbac944a535fa8fc8e7adca7c998ed815483b16c04d66be18dfd9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.",
                "category": "company",
                "datetime": 1786019160,
                "headline": "Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future"
              },
              {
                "id": 141134100,
                "url": "https://finnhub.io/api/news?id=fb525e1bdb7f00515828cb9ade2d230c825685eac77ea77d7ad7b7ad1d42b335",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "News of the day for Aug. 6, 2026",
                "category": "company",
                "datetime": 1786018980,
                "headline": "5 Things to Know Before the Stock Market Opens on Thursday"
              },
              {
                "id": 141136785,
                "url": "https://finnhub.io/api/news?id=7ea069109bf4e757834afdeff1a9a425be08ac6ee22c5a85cfd4b58d0117f3f1",
                "image": "https://image.cnbcfm.com/api/v1/image/108346049-17860291021786029100-47613163649-1080pnbcnews.jpg?v=1786029101&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "CNBC’s Annika Kim Constantino joins 'Squawk on the Street' to discuss the FDA approving Moderna's mRNA flu vaccine.",
                "category": "company",
                "datetime": 1786016123,
                "headline": "FDA approves Moderna mRNA flu shot"
              },
              {
                "id": 141138228,
                "url": "https://finnhub.io/api/news?id=aa8fef1bf003f6a68dc7428f865d74ce3a7df9bc180ec3376cfb2973c05af540",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/06/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna receives FDA approval for mFLUSIVA, a new seasonal flu vaccine for adults 50 and older, launching for the 2026-2027 virus season.",
                "category": "company",
                "datetime": 1786014383,
                "headline": "Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine"
              },
              {
                "id": 141133395,
                "url": "https://finnhub.io/api/news?id=9ad6e18b59b59ba95ea3c6a80942b33d39456293eef3c1776e10387382305278",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (NIU) expected in the second half of calendar year 2026First patients enrolled in the Phase 3 study of brepocitinib in cutaneous sarcoidosis (CS), with topline data expected in calendar year 2028; enrollment in Part 1 of the Phase 2b/3 study in lichen planopilaris (LPP) is progressing wellIMVT-1402 pr",
                "category": "company",
                "datetime": 1786014000,
                "headline": "Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update"
              },
              {
                "id": 141133200,
                "url": "https://finnhub.io/api/news?id=2a06843db7e338a41ee0c8ff68629f74c4a4442c3d3be25a55a67acd049203bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Memory stocks falter after guidance from Sandisk and Western Digital fails to meet the market’s sky-high expectations.",
                "category": "company",
                "datetime": 1786012920,
                "headline": "Sandisk, AppLovin, Moderna, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141133397,
                "url": "https://finnhub.io/api/news?id=c46773845d5cedef8aa5bfb3688c68aebb3d3eff8143231a9672fd0b38c0a086",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NASDAQ:MRNA) announced on Thursday that the U. S.",
                "category": "company",
                "datetime": 1786010836,
                "headline": "Moderna secures FDA approval for its first mRNA influenza vaccine"
              },
              {
                "id": 141136544,
                "url": "https://finnhub.io/api/news?id=9afbaad8619c7e88d0327fc9f16e16408a9548631ed15d11289a190b25b1d25d",
                "image": "https://image.cnbcfm.com/api/v1/image/108222317-1762435648172-gettyimages-2238075663-PELOTON_PRODUCTS.jpeg?v=1778073972&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are the stocks posting the largest moves in the premarket.",
                "category": "company",
                "datetime": 1786002650,
                "headline": "Stocks making the biggest moves premarket: Zillow, Peloton, Sandisk, Moderna & more"
              },
              {
                "id": 141132481,
                "url": "https://finnhub.io/api/news?id=ccf8ab372c3c2820cf388c4d522bcf3f278eb5c85ac3ba8813a56552ab68eb78",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "2026-08-06. The following slide deck was published by Moderna, Inc.",
                "category": "company",
                "datetime": 1785992836,
                "headline": "Moderna, Inc. 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141130974,
                "url": "https://finnhub.io/api/news?id=901409672929f92426a10f23decc4037b8173f778a55dc4b116dd6f1d4b8ab60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswire / August 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) ...",
                "category": "company",
                "datetime": 1785982500,
                "headline": "Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA"
              },
              {
                "id": 141120470,
                "url": "https://finnhub.io/api/news?id=ea02b890c98468dfcb6a3daf4a57e1155c97d4a78bb7d6052414b48250e69e07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc. (NASDAQ:MRNA) stock rose in Wednesday premarket trading after gaining 3.4% in the previous session, as investors reacted to the company’s latest progress in expanding its infectious disease pipeline with an investigational Ebola vaccine. Moderna Begins Phase 1 Trial For Ebola Vaccine Moderna has initiated a Phase 1 clinical trial evaluating mRNA-1469, an investigational vaccine designed to prevent Bundibugyo ebolavirus disease, for which no licensed vaccines currently exist. The stu",
                "category": "company",
                "datetime": 1785923262,
                "headline": "Moderna Advances Ebola Vaccine Into Human Testing"
              },
              {
                "id": 141122783,
                "url": "https://finnhub.io/api/news?id=1359891d2147dc7f7a10d4f13c8d3ac38bb25ee5ac8b1673eacca3cd7736c12a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Despite Moderna's stellar outperformance over the past year, Wall Street analysts remain cautious about the stock's longer-term prospects.",
                "category": "company",
                "datetime": 1785920357,
                "headline": "Are Wall Street Analysts Predicting Moderna Stock Will Climb or Sink?"
              },
              {
                "id": 141116462,
                "url": "https://finnhub.io/api/news?id=878b3f780bc1eaafe209c8223de498ae780eeb977329935233ac5b0317c54423",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "President Donald Trump discussed efforts to de-escalate US-Iran tensions with Qatari Emir Tamim bin Hamad Al Thani.",
                "category": "company",
                "datetime": 1785883534,
                "headline": "US Stock Futures Flat After S&P500, Dow End At Record Highs On Strong Earnings, Easing Geopolitical Concerns — PLTR, AZN, CMG, MRNA In Focus"
              },
              {
                "id": 141113095,
                "url": "https://finnhub.io/api/news?id=495a9f3d43e0cd55a8d639e8a0d979bfd84f00514344190add89cc6bd6820f3f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "These innovative biotech companies should reap the benefits of their breakthroughs.",
                "category": "company",
                "datetime": 1785871200,
                "headline": "Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does"
              },
              {
                "id": 141114899,
                "url": "https://finnhub.io/api/news?id=cc3466133ae9d0222d3d3b5b33ac9866171e629a6604cb4942181fac631f1c58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.",
                "category": "company",
                "datetime": 1785870060,
                "headline": "Moderna Stock Jumps on Hope for Breakthrough Ebola Vaccine—Key Word Being Hope"
              },
              {
                "id": 141112040,
                "url": "https://finnhub.io/api/news?id=f887021c29724e46fcc0203820936f8be8f20dc6727f6d7ef68a7d798b42c9e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna began a Phase 1 clinical trial of its experimental vaccine mRNA-1469 targeting the Bundibugyo strain of Ebola virus.",
                "category": "company",
                "datetime": 1785862022,
                "headline": "Moderna Doses First Participants In Ebola Vaccine Trial Ahead Of Key FDA Decision On Flu Shot"
              },
              {
                "id": 141111706,
                "url": "https://finnhub.io/api/news?id=9c275454cff15b564fb226211e33cf6b1539659100c3f312e3ee5e7e9a51b3c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.",
                "category": "company",
                "datetime": 1785861300,
                "headline": "Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine"
              },
              {
                "id": 141110326,
                "url": "https://finnhub.io/api/news?id=4fd7e9368dbe354b4538ff8c587b416efbf166d29f2bb2e18bc5e270d8f7c682",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our expanded collaboration with the Coalition for Epidemic Preparedness ...",
                "category": "company",
                "datetime": 1785855600,
                "headline": "Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus"
              },
              {
                "id": 141108636,
                "url": "https://finnhub.io/api/news?id=086305ba800b422dd0362144823856dc37cb6f97965ef7da8b38ac317f13d03a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.",
                "category": "company",
                "datetime": 1785844260,
                "headline": "Merck Stock Rises as Wall Street Looks Past Earnings Guidance Cut"
              },
              {
                "id": 141113874,
                "url": "https://finnhub.io/api/news?id=831816d0de79a48cf7d579cacb11d9de6477658ba44b3963cc520f628cbd3ce7",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna, Inc. (NASDAQ:MRNA) today announced that following Health Canada&#39;s authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, the",
                "category": "company",
                "datetime": 1785841353,
                "headline": "Moderna Vaccinates First Patients In Its Phase 1 Clinical Trial Of mRNA-1469 To Treat Bundibugyo Ebolavirus Following Health Canada Approval"
              },
              {
                "id": 141107778,
                "url": "https://finnhub.io/api/news?id=e338f789de4326b6d7e3998fec35e4fc4c9616d1e576b241f6769d4026226e43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.",
                "category": "company",
                "datetime": 1785840240,
                "headline": "Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?"
              },
              {
                "id": 141103086,
                "url": "https://finnhub.io/api/news?id=13f4ed8945887472491b9646b5fbac7e532d18f83a28e9a7f1baec450afd66f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.",
                "category": "company",
                "datetime": 1785792372,
                "headline": "MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading"
              },
              {
                "id": 141101221,
                "url": "https://finnhub.io/api/news?id=de4bfb820e8479cd503c5376fbd8bd409e7c3bb9d0d0b0453ad1b15abd3bf26e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) is facing several vaccine headwinds in the near to medium term, particularly for its",
                "category": "company",
                "datetime": 1785774052,
                "headline": "Moderna Facing Several Vaccine Headwinds in Near, Medium Term, RBC Says"
              },
              {
                "id": 141103670,
                "url": "https://finnhub.io/api/news?id=3296d2afc22fac4a9f1853d2534e5c8501f04e2ba9bc27cdf6f1941ea71c70d5",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Citigroup  analyst Geoff Meacham   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $41 to $60.",
                "category": "company",
                "datetime": 1785768145,
                "headline": "Citigroup Maintains Neutral on Moderna, Raises Price Target to $60"
              },
              {
                "id": 141090085,
                "url": "https://finnhub.io/api/news?id=cb92c7695a573ae9a1aa735a7a6b602d023a0f40809fbd6cc67e8b95a4057c73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna reported its Q2 update alongside news that its lead norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, so the trial will continue for further evaluation. The company is awaiting an FDA decision on its seasonal influenza vaccine, mFLUSIVA, which is expected by early August. Management paired these pipeline updates with Q2 results that were ahead of expectations and a revised outlook for operating expenses. For investors watching...",
                "category": "company",
                "datetime": 1785625773,
                "headline": "Moderna (MRNA) Faces Norovirus Setback As MFLUSIVA FDA Decision Nears"
              },
              {
                "id": 141120471,
                "url": "https://finnhub.io/api/news?id=ff40d06048e0c470e2da9c0a69160f12f39015cae1263d96a940b8c8f540128f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moby summary of Moderna, Inc.'s Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785587400,
                "headline": "Moderna, Inc. Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141087207,
                "url": "https://finnhub.io/api/news?id=79e77c460a159b12b5fdb784f7c44efc0b1aefa6cfa1fa600377134cf99ef33f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "After a whipsaw end to the month, the stock market’s decline was highlighted by the worst month for chip stocks in 24 years.",
                "category": "company",
                "datetime": 1785532200,
                "headline": "S&P 500 ends with its first July decline since 2014. Here are the stocks that led the selloff."
              },
              {
                "id": 141081727,
                "url": "https://finnhub.io/api/news?id=0e6b217ea0b704ea595a10ac7e41a3d97c4c6866d4197a0c10d8a2c6a799ae5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc (MRNA) exceeds Q2 revenue guidance and advances key vaccines, but faces delays in norovirus trial and oncology readouts.",
                "category": "company",
                "datetime": 1785524454,
                "headline": "Moderna Inc (MRNA) (Q2 2026) Earnings Call Highlights: Revenue Beat and Pipeline Progress Amid ..."
              },
              {
                "id": 141081549,
                "url": "https://finnhub.io/api/news?id=8e5807917ad3962f527a25faccd33954fa586c6c2a18376f52be2d06d6f439e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.",
                "category": "company",
                "datetime": 1785521040,
                "headline": "MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback"
              },
              {
                "id": 141082486,
                "url": "https://finnhub.io/api/news?id=21fe1895d9ac65bb599d35683c6e6f056e64d3d7c4837373bce0b5341710b638",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2204956103/image_2204956103.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "BioNTech trades near cash value; the oncology pipeline looks undervalued. Click here to read more about BNTX.",
                "category": "company",
                "datetime": 1785520130,
                "headline": "BioNTech: The Market Is Offering A 17-Program Oncology Pipeline For Almost Free"
              },
              {
                "id": 141079232,
                "url": "https://finnhub.io/api/news?id=159623b026e0607fa80577aa52ddf408b57d1f135c78429e79947233fe70e49b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The company topped Wall Street loss estimates, but its norovirus vaccine missed a key trial goal, sending shares lower",
                "category": "company",
                "datetime": 1785508239,
                "headline": "Moderna Q2 earnings beat estimates as norovirus vaccine stumbles"
              },
              {
                "id": 141079011,
                "url": "https://finnhub.io/api/news?id=97d9e222b054c1476b225754963b5acf752f93c797fd5c1c65e3d242e6a2ec01",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna  posted a narrower per-share loss in its latest quarter, but shares traded slightly lower as the company’s earnings report highlighted the drugmaker’s ongoing struggle to break away from its pandemic-driven business model.  Moderna  posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year.  The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.",
                "category": "company",
                "datetime": 1785506820,
                "headline": "Moderna Stock Has Doubled This Year. Can Earnings Keep the Rally Alive?"
              },
              {
                "id": 141079234,
                "url": "https://finnhub.io/api/news?id=c40ab8e955d13abb37b786cfe5287080bfadd5793abe8221034d396f5ee3dca9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases. The company posted a net loss of $782 million, or $1.97 per sha",
                "category": "company",
                "datetime": 1785506644,
                "headline": "Moderna Q2 Earnings Call Highlights"
              },
              {
                "id": 141077642,
                "url": "https://finnhub.io/api/news?id=3223cbf246df2f33c69539037f774a50260cd33d10286f045a518ad8062cad57",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Discover the top S&P500 movers in Friday's pre-market session and stay informed about market dynamics.",
                "category": "company",
                "datetime": 1785501301,
                "headline": "Get insights into the top movers in the S&P500 index of Friday's pre-market session."
              },
              {
                "id": 141078119,
                "url": "https://finnhub.io/api/news?id=6d37bef2f33c33b4f6b6bfdf56597d464c5ea9a0b5ac0b25c4bcdeebf542418b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785499801,
                "headline": "Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates"
              },
              {
                "id": 141079288,
                "url": "https://finnhub.io/api/news?id=fd73d347dd147f3649ce5c5b73510e7caedfd46a2f910fb34cf75b4a3016c588",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna, Inc. (MRNA) Q2 2026 Earnings Call July 31, 2026 8:00 AM EDTCompany ParticipantsLavina Talukdar - Senior VP & Head of Investor RelationsStéphane...",
                "category": "company",
                "datetime": 1785499402,
                "headline": "Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141077109,
                "url": "https://finnhub.io/api/news?id=f16d5a2dc9b6a4824034e9a6c0d771a4a457d491209a6f45740cd61bdbd2cfc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The benchmark US stock measures were tracking in the green before the open Friday as Amazon's (AMZN)",
                "category": "company",
                "datetime": 1785498389,
                "headline": "Stocks Rise Pre-Bell as Amazon Results Lift AI Trade Sentiment"
              },
              {
                "id": 141077360,
                "url": "https://finnhub.io/api/news?id=feadc898c39604ac58b85c95f9d3176aeea761452bbb6bc4f69f6cae69fdbaa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna  posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway.  Moderna  posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year.  The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.",
                "category": "company",
                "datetime": 1785497160,
                "headline": "Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?"
              },
              {
                "id": 141087997,
                "url": "https://finnhub.io/api/news?id=4caacbfb9100f8c9139b37721bfee97ef3989fd0afb2ded093e82f4cfa495084",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/31/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna (MRNA) Q2 Earnings: Beat estimates with $145M in sales and a $1.97 EPS loss. Reaffirms 2026 sales guidance.",
                "category": "company",
                "datetime": 1785496990,
                "headline": "Moderna Burns Cash, Suffers Fresh Vaccine Setback"
              },
              {
                "id": 141077361,
                "url": "https://finnhub.io/api/news?id=a0f0c5f8e5d5760b0b477b139ba5c2d18c0c6adf092582f7ad9a7b5a721d8a67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.1% year on year to $145 million. Its GAAP loss of $1.97 per share was 4.2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785496443,
                "headline": "Moderna (NASDAQ:MRNA) Beats Expectations in Q2 CY2026"
              },
              {
                "id": 141077362,
                "url": "https://finnhub.io/api/news?id=dc1dfb1ce678963e373dc8acf68f295f9fe51a03af150eb0eac84b7190ec20b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97) Reiterates plan to deliver up to 10% revenue growth in 2026 Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous ...",
                "category": "company",
                "datetime": 1785495600,
                "headline": "Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates"
              },
              {
                "id": 141078331,
                "url": "https://finnhub.io/api/news?id=ac530d31eb48c583c6b8bbc1b91343789c5a8e500ff7be600e75e89b17e3ab3b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2186886491/image_2186886491.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna is navigating a post-COVID transition, shifting focus to a diversified vaccine and therapeutics pipeline amid weak demand. Read more on MRNA stock here.",
                "category": "company",
                "datetime": 1785493846,
                "headline": "Moderna Q2: Weak Revenue, Strong Pipeline - Here's What Matters Now"
              },
              {
                "id": 141079909,
                "url": "https://finnhub.io/api/news?id=a5a7705f07d9b232c16355122cc3473a9188034e2f288c75be991d6c3a809f66",
                "image": "https://image.cnbcfm.com/api/v1/image/108313757-1780058150187-gettyimages-2275740460-TFSPI_14052026-5453.jpeg?v=1780058175&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1785483901,
                "headline": "Stocks making the biggest moves premarket: Replimune, Chevron, Apple, Amazon, Moderna & more"
              },
              {
                "id": 141078474,
                "url": "https://finnhub.io/api/news?id=4924c4d4a3733c4c77af4a5b8d10596bddf5c95e5af21a48d5f630a464a94aef",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna (NASDAQ:MRNA) affirms FY2026 sales outlook from $2.138 billion to $2.138 billion vs $2.089 billion estimate.",
                "category": "company",
                "datetime": 1785481264,
                "headline": "Moderna Affirms FY2026 Sales Guidance of $2.138B vs $2.089B Est"
              },
              {
                "id": 141068643,
                "url": "https://finnhub.io/api/news?id=6f0b72b80f20cb1734cc4c653ea213e50f7ebf7604dda827380b5c51cba56cfa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "There are fresh signs that fusion power startup Commonwealth Fusion Systems will list in the next two to three years.",
                "category": "company",
                "datetime": 1785426336,
                "headline": "When will fusion power startup Commonwealth Fusion Systems go public?"
              },
              {
                "id": 141067188,
                "url": "https://finnhub.io/api/news?id=cc026c98fea4324709a01e8a4a3c5c612c09d3cd2a3302964a661cc3b6940004",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results this Friday before market hours. Here’s what investors should know.",
                "category": "company",
                "datetime": 1785421262,
                "headline": "Moderna (MRNA) Q2 Earnings: What To Expect"
              },
              {
                "id": 141057077,
                "url": "https://finnhub.io/api/news?id=4a73e97bf16c01c4763ccc1ac48e9fce315900a166893fe20d536f40103001c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.",
                "category": "company",
                "datetime": 1785344580,
                "headline": "Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?"
              },
              {
                "id": 141056001,
                "url": "https://finnhub.io/api/news?id=42d1ace2654ba2bd9f203d862d7fec3bb81edcd8e97e9999a70c3c7f1e26b553",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock has delivered a strong 70.9% gain over the past year, but the longer track record and current valuation checks suggest the shares are not clearly priced as a bargain right now. Over five years, Moderna shareholders have seen the stock decline 85.6%, which puts the recent rebound in a much longer and still challenging context. Progress on the mRNA cancer program, including the recent Phase 1 trial start for mRNA-4200, can support sentiment on Moderna’s growth potential. At the...",
                "category": "company",
                "datetime": 1785341341,
                "headline": "Moderna (MRNA) Stock May Be Overvalued After Cancer Trial Start"
              },
              {
                "id": 141054570,
                "url": "https://finnhub.io/api/news?id=7a062cb0f57e72f12ca133cba9778cd83bcd77192d4de1dd4142cf922f41d010",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The year 2026 has turned into a pivotal year for the biotech capital markets. Venture funding for biotech firms reached $9.1 billion in the first half of the year, the highest total since 2022, with 38 acquisitions being completed over the same period, marking the sector’s greatest M&A pace in at least seven years. Underneath […]",
                "category": "company",
                "datetime": 1785337503,
                "headline": "Moderna Stock Has Doubled in 2026, But Wall Street Still Isn’t Convinced"
              },
              {
                "id": 141053279,
                "url": "https://finnhub.io/api/news?id=a0f0df1b96fb612ea00f606fa308ad08c08fff23339b1ab08cadc9cee3998d9d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In recent months, Moderna reported a very large year-on-year Q1 revenue increase that surpassed analyst expectations, secured two European approvals including the world’s first flu plus COVID combination vaccine mCOMBRIAX, and began a pivotal Phase 3 trial for its lung cancer candidate intismeran. This combination of new product approvals and late-stage oncology pipeline progress highlights Moderna’s effort to broaden its business well beyond its COVID-19 franchise. We’ll now examine how the...",
                "category": "company",
                "datetime": 1785330585,
                "headline": "Why Moderna (MRNA) Is Down 6.5% After Europe Clears Its First Flu-COVID Combo Vaccine"
              },
              {
                "id": 141052277,
                "url": "https://finnhub.io/api/news?id=2625622a16fd23e22e1bea637d0a6ab5014872dcc8587d4bdb5968cc04ba868c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.",
                "category": "company",
                "datetime": 1785326417,
                "headline": "3 Biotech Stocks With Massive Upside to Buy Before August Starts"
              },
              {
                "id": 141049147,
                "url": "https://finnhub.io/api/news?id=847f022feb42bf4d47a784124e1326cc42350ccd7a0f939c17b8e3547748713d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 14.3% over the past six months while the S&P 500 was up 6.3%.",
                "category": "company",
                "datetime": 1785285902,
                "headline": "1 Healthcare Stock to Keep an Eye On and 2 We Avoid"
              },
              {
                "id": 141045629,
                "url": "https://finnhub.io/api/news?id=9896d38833b64101df2a2a0f1f49cf45257fda96b8dd51902d04c599480ea14a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has already surged more than 80% in 2026, but two major events packed into the next two weeks could either cement that rally or unravel it fast.",
                "category": "company",
                "datetime": 1785255709,
                "headline": "2 Major Reasons to Buy Moderna Stock Before July 31"
              },
              {
                "id": 141039020,
                "url": "https://finnhub.io/api/news?id=8fd1782ce05250991501094467121195fe3381f0424a31fb4a32d1bbfbab84c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at therapeutics stocks, starting with Moderna (NASDAQ:MRNA).",
                "category": "company",
                "datetime": 1785200942,
                "headline": "Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks"
              },
              {
                "id": 141038245,
                "url": "https://finnhub.io/api/news?id=47f74155c62b90bd68e5ca30079eeafceadd9ffd98e1024e5dcf70f7e7908c58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In the most recent trading session, Moderna (MRNA) closed at $55.63, indicating a +2.89% shift from the previous trading day.",
                "category": "company",
                "datetime": 1785189004,
                "headline": "Moderna (MRNA) Laps the Stock Market: Here's Why"
              },
              {
                "id": 141037355,
                "url": "https://finnhub.io/api/news?id=39fec9f047840672f1016880d7063a68767b5c8011a8796005ee76165a2717a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's stock recently hit a new 52-week high after receiving positive news surrounding one of its vaccines.",
                "category": "company",
                "datetime": 1785183747,
                "headline": "After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?"
              },
              {
                "id": 141036351,
                "url": "https://finnhub.io/api/news?id=5b184e2138a7cf1b916297cca94bbf2d1b1ca16fe8b25b8f27bd6fce1dd88ee6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Moderna (NASDAQ:MRNA) and its peers.",
                "category": "company",
                "datetime": 1785177902,
                "headline": "Therapeutics Stocks Q1 Highlights: Moderna (NASDAQ:MRNA)"
              },
              {
                "id": 141015956,
                "url": "https://finnhub.io/api/news?id=30c853daab5af443ab8a0c8862a8b56eabb48569926bf56471b440d71080bbab",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/attachment/image/1d2aed9fc253168620c030b0153c6b23.png?io=w640",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Wall Street Breakfast recap: stocks slide on oil surge, tech earnings, tariffs and Middle East tensions.",
                "category": "company",
                "datetime": 1784970358,
                "headline": "What Moved Markets This Week"
              },
              {
                "id": 141015118,
                "url": "https://finnhub.io/api/news?id=cbf5dc445b0c76d160194163974c25631e03fe21e4e10a18d4aafdb19b3e4b54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The days ahead pack several binary or near-binary catalysts for U.S. biotech and biopharma companies—decisions that could sharply reshape valuations overnight.",
                "category": "company",
                "datetime": 1784939440,
                "headline": "FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions"
              },
              {
                "id": 141006520,
                "url": "https://finnhub.io/api/news?id=3aefd1a3b5bd534f69d2fcade197da65aeb3b00065b71bc03914a4c1346e14aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784901614,
                "headline": "Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know"
              },
              {
                "id": 140995023,
                "url": "https://finnhub.io/api/news?id=925ed259cfd744a1d6a25d64224d1e30210b5a3fba92b33ce75ac67e37fd04df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Despite challenges in life sciences and European automotive sectors, Dassault Systemes SE (DASTF) reports robust revenue growth and strategic advancements in AI and cloud solutions.",
                "category": "company",
                "datetime": 1784818907,
                "headline": "Dassault Systemes SE (DASTF) (H1 2026) Earnings Call Highlights: Strong Subscription Growth and ..."
              },
              {
                "id": 140994788,
                "url": "https://finnhub.io/api/news?id=531056513eb02609f4a4938c9a9d323461a433a76b4cbd553c5d298c12047e7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.",
                "category": "company",
                "datetime": 1784818856,
                "headline": "Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?"
              },
              {
                "id": 140998135,
                "url": "https://finnhub.io/api/news?id=97ee12753c510423248db8b35f41ebfbcd51905e784a842f30e78fe3eeee4d92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.",
                "category": "company",
                "datetime": 1784807075,
                "headline": "Earnings Preview: What To Expect From Moderna’s Report"
              },
              {
                "id": 140983367,
                "url": "https://finnhub.io/api/news?id=121dee6eb5b95230890bc77a0fb432c067d167b2adb9237f093d012c795d3f33",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Cheiron Founders Cheiron co-founders (from left): Harshit Gupta, co-founder and chief technology officer; Minseok Bae, co-founder and CEO; and Jason Park, co-founder and chief product officer. LOS ALTOS, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cheiron, the operating system for drug programs, today announced an $8 million seed round led by Menlo Ventures, with the backing and strategic support of industry veterans including Moderna co-founder and MIT Institute Professor Robert Langer; former Pf",
                "category": "company",
                "datetime": 1784736000,
                "headline": "Cheiron Raises $8M Seed Led by Menlo Ventures to Build the Operating System for Drug Programs"
              },
              {
                "id": 140980977,
                "url": "https://finnhub.io/api/news?id=7a6528725d9c46a032b9aec4860fb2d1d0620a931ee06da19f7676b4d8235c80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CHICAGO, July 22, 2026--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with institutional investors. In every healthcare subsector, roughly half to two-thirds of investors (48% to 67%) agree that management overemphasizes AI relative to its actual financial contribution, the most consistent finding in \"Hallucinating Value: Healthcare's AI Narrative.\"",
                "category": "company",
                "datetime": 1784714400,
                "headline": "Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown"
              },
              {
                "id": 140979307,
                "url": "https://finnhub.io/api/news?id=ab1d76e1b33557d5f6d4d8c656c9abaf685f1cb4f7b217f4e4756b6285cf66c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) drew fresh attention after appointing experienced financial executive Michael McDonnell to its Board and Audit Committee, as the stock recently declined 3.77% and an earnings report is scheduled for July 31, 2026. See our latest analysis for Moderna. Moderna shares have been volatile, with the 7-day share price return down 11.54% and the 30-day share price return down 6.72%. However, the year to date share price return of 93.32% and 1-year total shareholder return of 82.28%...",
                "category": "company",
                "datetime": 1784694596,
                "headline": "Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near?"
              },
              {
                "id": 140978883,
                "url": "https://finnhub.io/api/news?id=d78c0114452c0261f94eb1ca62c5f3010494eee1e76749bee9dc0779be07cab5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has appointed Michael McDonnell to its Board of Directors and Audit Committee. The company has adjusted certain Board committee memberships alongside his appointment. The changes bring additional financial and life sciences experience into Moderna’s governance structure. Moderna, traded on NasdaqGS:MRNA, is drawing attention for a fresh governance update rather than product news. The stock closed at $59.66, with returns up 93.3% year to date and up 82.3% over the past year, set...",
                "category": "company",
                "datetime": 1784690424,
                "headline": "Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift"
              },
              {
                "id": 140978393,
                "url": "https://finnhub.io/api/news?id=143dd199ffc3732f0edb7b90bcea9a1e351dd89c2f0cb9ff5d841117d8cf8ee1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The biotech has been on a tear lately.",
                "category": "company",
                "datetime": 1784679600,
                "headline": "Should You Buy Moderna Stock Hand Over Fist Before Aug. 5?"
              },
              {
                "id": 140971289,
                "url": "https://finnhub.io/api/news?id=9a2a8d5b3f1dc00f623f077a22173abc8310497221db1355efc77c8c69b89b10",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Goldman Sachs  analyst Salveen Richter   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $49 to $67.",
                "category": "company",
                "datetime": 1784623280,
                "headline": "Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $67"
              },
              {
                "id": 140966165,
                "url": "https://finnhub.io/api/news?id=34658b765cdec9863d3712d07ca568307568935179720cee2fd26da1dc4f64b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A fresh era of earnings growth may be on the horizon.",
                "category": "company",
                "datetime": 1784586600,
                "headline": "Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?"
              },
              {
                "id": 140966337,
                "url": "https://finnhub.io/api/news?id=dba9895e956dbc5290626a3989cd198396272214c3838d279d6740cf6005a48f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.",
                "category": "company",
                "datetime": 1784584203,
                "headline": "Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights"
              },
              {
                "id": 140934665,
                "url": "https://finnhub.io/api/news?id=156d625b8c8ea3b5425a1edc5e9873aeed003751d527274d43714d475eccc7dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1784307466,
                "headline": "Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140934500,
                "url": "https://finnhub.io/api/news?id=b8d38ebc14f6fb86a9aaa49ca942ab31591c522f24a09a7b19d48899869a54d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.",
                "category": "company",
                "datetime": 1784300340,
                "headline": "MRNA Advances Cancer Pipeline With New Immunotherapy Study"
              },
              {
                "id": 140931633,
                "url": "https://finnhub.io/api/news?id=a3bb467eca89014e58136c2e5ec2ca3928bc78c3fbb500a9965da2dcc2a2a54d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "(Bloomberg) -- As worries build around the artificial intelligence trade, investors are starting to seek shelter in a more pedestrian corner of the stock market: companies with sturdy finances.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthNasdaq Futures Tumble 1.5% as Chip Rout Deepens: Markets WrapUS Cyclospora Outbreak Tied to",
                "category": "company",
                "datetime": 1784288659,
                "headline": "Neglected Quant Safety Trade Makes a Comeback as AI Risks Rise"
              },
              {
                "id": 140933093,
                "url": "https://finnhub.io/api/news?id=a4cd3c507c482d8f1957c9ad2e3b0bb58a656a4187d89ec4a698b1241eeb7f45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.",
                "category": "company",
                "datetime": 1784282845,
                "headline": "Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances"
              },
              {
                "id": 140924528,
                "url": "https://finnhub.io/api/news?id=f1e1715ec5ef89b9077a66a3ae648149c25e397177105374f1afe0fa2ef540fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.",
                "category": "company",
                "datetime": 1784227263,
                "headline": "ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?"
              },
              {
                "id": 140921837,
                "url": "https://finnhub.io/api/news?id=192e750e79a3e75ab0d468b53d4de78fd222cc21fdcb5c63cb9253fb73f4301d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.",
                "category": "company",
                "datetime": 1784219700,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 140918921,
                "url": "https://finnhub.io/api/news?id=a55e4c8b6ce0a21c79c97c228a610dad6931a94cff4a46dfd5fe6ccc4b01ebfb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Moderna’s infringement of Arbutus’ LNP patents Anticipates receipt of a dividend from Genevant in Q3 2026 Expects to return up to approximate",
                "category": "company",
                "datetime": 1784201400,
                "headline": "Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders"
              },
              {
                "id": 140919029,
                "url": "https://finnhub.io/api/news?id=ec7dfff01ad9a972b4e1106cb3ba1b7e1a0767fd8854874d2a6bcf4e0c1e0d8b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced ...",
                "category": "company",
                "datetime": 1784199600,
                "headline": "Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors"
              },
              {
                "id": 140921643,
                "url": "https://finnhub.io/api/news?id=ad1db4b6be88d8cd0e3ddb4d5813892f40565c9119be0162b0369232b28fd01e",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic",
                "category": "company",
                "datetime": 1784185418,
                "headline": "Moderna Doses First US Participant In Its Phase 1 Study Of mRNA-4200, Tumor-Targeted Cancer Antigen Therapy Candidate, For Advanced Or Metastatic Solid Tumors"
              },
              {
                "id": 140900040,
                "url": "https://finnhub.io/api/news?id=76e7485fea8bbc7883846148f4118bada996ba5602ddc83871a64492383b4f0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company’s late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a...",
                "category": "company",
                "datetime": 1784050500,
                "headline": "Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies"
              },
              {
                "id": 140893920,
                "url": "https://finnhub.io/api/news?id=47d6d4e74ed1db540632834dce38790a050e1f5ba2d4668c97c2e1fc020011b7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256895141/image_2256895141.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Markets remained mixed last week, with sector leadership continuing to rotate beneath a relatively stable broader market.",
                "category": "company",
                "datetime": 1783989300,
                "headline": "ValuEngine Weekly Market Summary And Commentary"
              },
              {
                "id": 140892671,
                "url": "https://finnhub.io/api/news?id=f5eb20fba93f312e07c310ee8bf8c0e66eadb4e3e9883c34d31c9724d1fcd058",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.",
                "category": "company",
                "datetime": 1783979406,
                "headline": "Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note"
              },
              {
                "id": 140885957,
                "url": "https://finnhub.io/api/news?id=c3654f647a3a47105890017a1058d688704c7d5e8383e61c6ed4d24e55ec464f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.",
                "category": "company",
                "datetime": 1783948328,
                "headline": "What It Means To Hold Moderna Stock In A Crash"
              },
              {
                "id": 140886045,
                "url": "https://finnhub.io/api/news?id=cbed7f50e76169885f3ee752a5d4dc459a65e615e71f72c26bb80ca6f09f9856",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in the battle to bring a new sleep treatment to market.",
                "category": "company",
                "datetime": 1783930800,
                "headline": "Moderna, Takeda and Capricor on the verge of notching big drug approvals"
              },
              {
                "id": 140884386,
                "url": "https://finnhub.io/api/news?id=af5eb902aca1992ec5be596a883f3a2dc814c0cdaac87d634e05625c0cd64bc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The Morning Bull - US Market Morning Update Monday, Jul, 13 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.4%, as investors digest a mix of cooling inflation and uneven growth signals abroad. Softer price data in countries like France, where inflation sits at 1.8%, suggests global cost of living pressures are easing, which can take some pressure off central banks to keep lifting interest rates. At the same time, weaker industrial output in...",
                "category": "company",
                "datetime": 1783930232,
                "headline": "US Stock Market Today: S&P 500 Futures Rise As Inflation Cools And Earnings Loom"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 1,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": -0.3,
            "source_article_count": 113,
            "discarded_article_count": 77
          },
          "sentimentPoints": 1
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.2,
          "macdPoints": 3.2,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(54.4%→13.4%)；跌縮量(近10日3日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 6657660,
              "down_days": 4,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 5515020,
              "avg_vol_20": 5090135,
              "avg_vol_30": 6657660,
              "range_pct_10": 0.1338946673270597,
              "range_pct_20": 0.261350503549612,
              "range_pct_30": 0.5438335809806835,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8283721307486415,
              "dist_to_20d_high": 0.1156373193166885,
              "down_shrink_days": 3,
              "breakout_level_20d": 68.49,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.2462052216150579
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 3.2,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 0.9,
            "details": {
              "atrPct": 5.913488525672775,
              "turnoverUsdM": 396.71708553,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.3
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.MRNA",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 53.4064,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 2.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 11.8,
            "take_profit_price": 68.6231,
            "target_multiplier": 1.9,
            "technical_strength": 1.78,
            "take_profit_percent": 13.3
          },
          "positionPoints": 0.9,
          "stopLossPoints": 0.6,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 11.82697705134555,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.MRNA",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 3.5818,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 2,
      "atr_pct": 5.91
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 47.82
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1627
    },
    "kdj": {
      "d": 57.32,
      "j": 107.94,
      "k": 74.19,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 51.42
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 82456929,
      "recentSlope": 1466182.9,
      "previousSlope": -1741590
    },
    "rsi": 54.88,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 53.9768,
      "position": "SAR喺價下",
      "distancePct": 10.89,
      "previousTrend": "上升"
    },
    "ma50": 59.8079,
    "macd": {
      "macd": -1.105023936866452,
      "trend": "看漲",
      "signal": -1.4191711652273717,
      "histogram": 0.3141472283609197
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 6,
      "value": 58.1893,
      "position": "連續1-2日>VWAP",
      "consecutiveAbove": 2
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.28,
      "score": 6,
      "avgVolume": 5127006,
      "currentVolume": 6549729
    },
    "derived": {
      "ma20": 58.101,
      "ma50": 59.8079,
      "prevClose": 59.81,
      "avgVolume10": 5614633,
      "avgVolume20": 5127006,
      "changePercent": 1.27,
      "avgVolumeForScore": 5127006
    },
    "ma_cross": {
      "ma20": 58.101,
      "ma50": 59.8079,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 58.4445,
      "prevMa50": 59.5403,
      "spreadPct": 2.85,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 51.1514,
      "upper": 65.0506,
      "position": "上半部"
    },
    "rsi_short": 73.22,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.28
    }
  }
}

{
  "close": 60.57,
  "volume": 6549729,
  "changePercent": 1.27
}